2024-11-14 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, consumables, software, and services for research, analysis, discovery, and diagnostics.

**Performance Analysis:**

* **Rate Comparison:** TMO has outperformed the S&P 500 (VOO) with a cumulative return of 216.38% compared to VOO's 179.47%, resulting in a difference of 36.91%. This places TMO's performance at the 20.39% percentile of its historical performance range.
* **Alpha & Beta Analysis:**
    * TMO exhibits strong alpha (above 0.8) across all time periods, indicating the stock has consistently outperformed the market.
    * The beta is consistently close to 1, implying TMO's volatility is similar to the overall market.
* **Recent Price Movement:**
    * Closing price: 541.9
    * 5-day moving average: 547.44
    * 20-day moving average: 561.96
    * 60-day moving average: 593.04
    * This indicates a short-term downtrend as the closing price is below all three moving averages.
* **Technical Indicators:**
    * RSI: 36.5, suggesting the stock is potentially oversold.
    * PPO: -0.11, indicating a negative momentum.
    * Delta_Previous_Relative_Divergence: -17.23, confirming a short-term downtrend.
    * Expected Return: 10.73%, implying a potential long-term outperformance relative to the S&P 500.
* **Recent Earnings:**
    | Date | EPS | Revenue |
    |---|---|---|
    | 2024-11-01 | 4.26 | $10.60 B |
    | 2024-08-02 | 4.05 | $10.54 B |
    | 2024-05-03 | 3.47 | $10.35 B |
    | 2023-11-03 | 4.44 | $10.57 B |
    | 2024-11-01 | 4.44 | $10.57 B |
    
    The latest earnings for the quarter ending November 1, 2024, came in at $4.26 EPS and $10.60 billion in revenue. While the company surpassed earnings expectations, the revenue was slightly below projections.
* **Financial Information:**
    * **Revenue and Profitability:** Consistent high revenue and profitability with profit margin consistently around 40%.
    * **Capital and Profitability:** Stable equity growth and consistent ROE over the past 5 quarters.
* **News and Recent Issues:**
    * Recent earnings reports have been generally positive, with TMO exceeding earnings expectations. 
    * Industry news suggest strong demand for TMO's products and services, driven by growth in research, healthcare, and diagnostics markets.
    * Analysts remain optimistic about TMO's future prospects, citing its strong market position, innovation, and growth potential.

**Overall Analysis:**

Thermo Fisher Scientific Inc. (TMO) is a strong performer with a history of outperforming the market. Despite recent downtrends in the stock price, TMO remains fundamentally sound with a solid financial track record, strong growth prospects, and positive analyst sentiment. While short-term technical indicators point to a potential oversold situation, the long-term expected return suggests a potential for sustained outperformance. 

**Recommendation:**  Given the current market conditions and TMO's long-term growth potential, a long-term investment strategy with a focus on dollar-cost averaging might be considered. However, it is essential to monitor the company's future performance and market developments closely.
